Genentech, Inc.
NEWS
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Genentech announced positive topline results from its Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug mycophenolate mofetil in patients with pemphigus vulgaris.
Data from the clinical study showed that 40% of people treated with the Polivy regimen achieved a complete response.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Xofluza showed a significant preventive effect after a single oral dose. Only about 1.9% of patients who received Xofluza showed signs of the flu, compared to 13.6% of the placebo group.
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus’ technology to target IBD and Celiac.
The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
JOBS
IN THE PRESS